Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Plus Therapeutics Inc PSTV

Healthcare Biotechnology
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers. The Company combines image-guided local beta radiation and targeted drug delivery approaches. The Company is advancing a pipeline of product candidates with lead programs in recurrent glioblastoma... see more

Recent & Breaking News (NDAQ:PSTV)

Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference

GlobeNewswire 1 day ago

Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide(TM) Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases

GlobeNewswire 4 days ago

Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide(TM) Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases

GlobeNewswire 5 days ago

Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 11 days ago

Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership

GlobeNewswire November 6, 2024

Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024

GlobeNewswire November 5, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas

GlobeNewswire October 29, 2024

Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting

GlobeNewswire October 1, 2024

Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting

GlobeNewswire September 18, 2024

Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire September 4, 2024

Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 14, 2024

Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference

GlobeNewswire August 13, 2024

Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference

GlobeNewswire August 12, 2024

Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024

GlobeNewswire August 8, 2024

Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference

GlobeNewswire July 25, 2024

Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer

GlobeNewswire July 2, 2024

Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT

GlobeNewswire June 7, 2024

Plus Therapeutics Announces New Employment Inducement Grants

GlobeNewswire May 17, 2024

Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire May 15, 2024

Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

GlobeNewswire May 13, 2024